Details

Autor(en) / Beteiligte

• Dalgard, Olav
• Litwin, Alain H.
• Shibolet, Oren
• Grebely, Jason
• Nahass, Ronald
• Altice, Frederick L.
• Conway, Brian
• Gane, Edward J.
• Luetkemeyer, Anne F.
• Peng, Cheng-Yuan
• Iser, David
• Gendrano, Isaias Noel
• Kelly, Michelle M.
• Haber, Barbara A.
• Platt, Heather
• Puenpatom, Amy

Titel

Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection

Ist Teil von

• Journal of addictive diseases, 2023-07, Vol.41 (3), p.213-224

Ort / Verlag

England: Taylor & Francis

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Taylor & Francis Journals Auto-Holdings Collection

Beschreibungen/Notizen

• In people with chronic hepatitis C virus (HCV) infection, viral eradication is associated with improved health-related quality of life (HRQOL). To assess changes in HRQOL among participants receiving opioid agonist therapy undergoing treatment for HCV infection COSTAR (NCT02251990) was a randomized, double-blind, placebo-controlled study. Adults with HCV infection on opioid agonist therapy received elbasvir (50 mg)/grazoprevir (100 mg) or placebo for 12 weeks. HRQOL was evaluated using the Medical Outcomes Study 36-Item Short Form Health Survey version 2 (SF-36v2) Acute Form. Participants remained blinded until 4 weeks after end of treatment. Overall, 201 participants received elbasvir/grazoprevir and 100 participants received placebo. Treatment difference mean change from baseline scores (elbasvir/grazoprevir minus placebo) indicated an improvement in HRQOL at 4 weeks after end of treatment in participants receiving elbasvir/grazoprevir versus those receiving placebo, driven by declining HRQOL in those receiving placebo and improved HRQOL in certain domains among participants receiving elbasvir/grazoprevir. Notable differences in SF-36v2 scores were evident in the general health (mean treatment difference [MTD], 6.00; 95% CI, 1.37-10.63), vitality (MTD, 6.81; 95% CI, 1.88-11.75), and mental health (MTD, 5.17; 95% CI, 0.52-9.82) domains and in the mental component summary score (mean, 2.83; 95% CI, 0.29-5.37). No notable between-treatment differences were evident at treatment weeks 4 or 12. HRQOL in patients receiving medication for opioid dependence was improved following treatment for HCV infection with elbasvir/grazoprevir, suggesting that eradication of HCV infection with direct-acting antivirals is associated with improved HRQOL. ClinicalTrials.gov, NCT02251990